Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jaguar Animal Health

8.51
-0.1850-2.13%
Post-market: 8.790.2800+3.29%18:57 EDT
Volume:72.26K
Turnover:640.30K
Market Cap:5.74M
PE:-0.07
High:9.36
Open:9.36
Low:8.34
Close:8.70
Loading ...

Jaguar Health Inc expected to post a loss of $18.00 a share - Earnings Preview

Reuters
·
Yesterday

Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

ACCESS Newswire
·
30 Apr

Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast

ACCESS Newswire
·
28 Apr

Jaguar Animal Health trading halted, volatility trading pause

TIPRANKS
·
26 Apr

Jaguar Animal Health trading resumes

TIPRANKS
·
26 Apr

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

ACCESS Newswire
·
17 Apr

Jaguar Health to present results from OnTarget study in breast cancer patients

TipRanks
·
16 Apr

Jaguar Health files to sell 1.29M shares of common stock for holders

TIPRANKS
·
16 Apr

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

ACCESS Newswire
·
15 Apr

Jaguar Animal Health trading halted, volatility trading pause

TIPRANKS
·
11 Apr

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

ACCESS Newswire
·
08 Apr

Jaguar Animal Health Secures $3.448M in Private Placement

TIPRANKS
·
05 Apr

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACCESS Newswire
·
05 Apr

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

ACCESS Newswire
·
02 Apr

Jaguar Health Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Apr

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

ACCESS Newswire
·
31 Mar

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

ACCESS Newswire
·
28 Mar

Jaguar Health Inc expected to post a loss of $18.50 a share - Earnings Preview

Reuters
·
28 Mar

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

ACCESS Newswire
·
27 Mar

Sector Update: Health Care Stocks Retreat Wednesday Afternoon

MT Newswires Live
·
27 Mar